Irish medical technology firm Medtronic has introduced HawkOne directional atherectomy system in the US, which is developed for the treatment of peripheral arterial disease (PAD).
The HawkOne system helps physicians to treat all plaque morphologies in patients with PAD, including patients who have plaque blockages that have become severely calcified.
Medtronic peripheral vascular general manager and vice-president Brian Verrier said: "Based on physician feedback and collaboration, we have developed a technology that enables physicians to treat lower extremity PAD more efficiently and effectively.
"The HawkOne system enhances our directional atherectomy platforms and reinforces our commitment to therapy innovation by providing physicians and patients with new treatment solutions that protect limbs and enhance lives."
The HawkOne system allows operators to treat severe calcium more effectively and can treat calcified lesions up to two times more effectively compared to firm’s TurboHawk device.
Its design also streamlines procedural efficiency with improved crossing and cleaning capabilities and lower crossing profile improves sheath deliverability, allowing physicians to cross challenging lesions more predictably.